Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 82

1.

Pharmacodynamics, pharmacokinetics, safety, and tolerability of encenicline, a selective α7 nicotinic receptor partial agonist, in single ascending-dose and bioavailability studies.

Barbier AJ, Hilhorst M, Van Vliet A, Snyder P, Palfreyman MG, Gawryl M, Dgetluck N, Massaro M, Tiessen R, Timmerman W, Hilt DC.

Clin Ther. 2015 Feb 1;37(2):311-24. doi: 10.1016/j.clinthera.2014.09.013. Epub 2014 Oct 14.

2.
3.

Electroconvulsive seizures regulate gene expression of distinct neurotrophic signaling pathways.

Altar CA, Laeng P, Jurata LW, Brockman JA, Lemire A, Bullard J, Bukhman YV, Young TA, Charles V, Palfreyman MG.

J Neurosci. 2004 Mar 17;24(11):2667-77.

4.

Novel directions in antipsychotic target identification using gene arrays.

Palfreyman MG, Hook DJ, Klimczak LJ, Brockman JA, Evans DM, Altar CA.

Curr Drug Targets CNS Neurol Disord. 2002 Apr;1(2):227-38. Review.

PMID:
12769629
5.

Psychiatric Genomics, inc.

Palfreyman MG.

Pharmacogenomics. 2002 May;3(3):417-20.

PMID:
12052148
6.

Human tissue in target identification and drug discovery.

Palfreyman MG.

Drug Discov Today. 2002 Apr 1;7(7):407-9. Review. No abstract available.

PMID:
11916568
7.

The primary in vitro anticancer activity of "half-mustard type" phenothiazines in NCI's revised anticancer screening paradigm.

Wuonola MA, Palfreyman MG, Motohashi N, Kawase M, Gabay S, Gupta RR, Molnár J.

Anticancer Res. 1998 Jan-Feb;18(1A):337-48.

PMID:
9568100
8.

The in vitro antitumor assay of "half-mustard type" phenothiazines in screens of AIDS-related leukemia and lymphomas.

Wuonola MA, Palfreyman MG, Motohashi N, Kawase M, Gabay S, Molnár J.

Anticancer Res. 1997 Sep-Oct;17(5A):3425-9.

PMID:
9413181
9.

The primary in vitro antitumor screening of "half-mustard type" phenothiazines.

Wuonola MA, Palfreyman MG, Motohashi N, Kawase M, Gabay S, Nacsa J, Molnár J.

Anticancer Res. 1997 Sep-Oct;17(5A):3409-23.

PMID:
9413180
10.

MDL 100,458 and MDL 102,288: two potent and selective glycine receptor antagonists with different functional profiles.

Kehne JH, Baron BM, Harrison BL, McCloskey TC, Palfreyman MG, Poirot M, Salituro FG, Siegel BW, Slone AL, Van Giersbergen PL, et al.

Eur J Pharmacol. 1995 Sep 15;284(1-2):109-18.

PMID:
8549613
11.

The role of 5-HT2A receptors in antipsychotic activity.

Schmidt CJ, Sorensen SM, Kehne JH, Carr AA, Palfreyman MG.

Life Sci. 1995;56(25):2209-22. Review.

PMID:
7791509
12.

Enzyme-activated antagonists of the strychnine-insensitive glycine/NMDA receptor.

Salituro FG, Tomlinson RC, Baron BM, Palfreyman MG, McDonald IA, Schmidt W, Wu HQ, Guidetti P, Schwarcz R.

J Med Chem. 1994 Feb 4;37(3):334-6. No abstract available.

PMID:
8308859
13.

Haloallylamine inhibitors of MAO and SSAO and their therapeutic potential.

Palfreyman MG, McDonald IA, Bey P, Danzin C, Zreika M, Cremer G.

J Neural Transm Suppl. 1994;41:407-14.

PMID:
7931257
14.

The acute effect of the bioprecursor of the selective brain MAO-A inhibitor, MDL 72392, on rat pineal melatonin biosynthesis.

Oxenkrug GF, Requintina PJ, Yuwiler A, Palfreyman MG.

J Neural Transm Suppl. 1994;41:377-9.

PMID:
7931254
15.

MDL 72,974A: a selective MAO-B inhibitor with potential for treatment of Parkinson's disease.

Palfreyman MG, McDonald IA, Zreika M, Cremer G, Haegele KD, Bey P.

J Neural Transm Suppl. 1993;40:101-11.

PMID:
8294896
16.

Electrophysiological, biochemical and behavioral evidence for 5-HT2 and 5-HT3 mediated control of dopaminergic function.

Palfreyman MG, Schmidt CJ, Sorensen SM, Dudley MW, Kehne JH, Moser P, Gittos MW, Carr AA.

Psychopharmacology (Berl). 1993;112(1 Suppl):S60-7.

PMID:
7831442
17.

MDL 27,531 reduces spontaneous hindlimb contractions in rats with chronic transections of the spinal cord.

Kehne JH, Ketteler HJ, Kane JM, McCloskey TC, Senyah Y, Palfreyman MG.

Neurosci Lett. 1992 Nov 23;147(1):101-5.

PMID:
1480315
18.

Potent indole- and quinoline-containing N-methyl-D-aspartate antagonists acting at the strychnine-insensitive glycine binding site.

Baron BM, Harrison BL, McDonald IA, Meldrum BS, Palfreyman MG, Salituro FG, Siegel BW, Slone AL, Turner JP, White HS.

J Pharmacol Exp Ther. 1992 Sep;262(3):947-56.

PMID:
1388205
19.

[3H]5,7-dichlorokynurenic acid, a novel radioligand labels NMDA receptor-associated glycine binding sites.

Baron BM, Siegel BW, Slone AL, Harrison BL, Palfreyman MG, Hurt SD.

Eur J Pharmacol. 1991 Feb 25;206(2):149-54.

PMID:
1829684
20.

NMDA receptor complex antagonists have potential anxiolytic effects as measured with separation-induced ultrasonic vocalizations.

Kehne JH, McCloskey TC, Baron BM, Chi EM, Harrison BL, Whitten JP, Palfreyman MG.

Eur J Pharmacol. 1991 Feb 14;193(3):283-92.

PMID:
1675993
21.

Activity of 5,7-dichlorokynurenic acid, a potent antagonist at the N-methyl-D-aspartate receptor-associated glycine binding site.

Baron BM, Harrison BL, Miller FP, McDonald IA, Salituro FG, Schmidt CJ, Sorensen SM, White HS, Palfreyman MG.

Mol Pharmacol. 1990 Oct;38(4):554-61.

PMID:
2172769
22.

Curtatoxins. Neurotoxic insecticidal polypeptides isolated from the funnel-web spider Hololena curta.

Stapleton A, Blankenship DT, Ackermann BL, Chen TM, Gorder GW, Manley GD, Palfreyman MG, Coutant JE, Cardin AD.

J Biol Chem. 1990 Feb 5;265(4):2054-9.

23.

History of serotonin and serotinin disorders.

Sjoerdsma A, Palfreyman MG.

Ann N Y Acad Sci. 1990;600:1-7; discussion 7-8. Review. No abstract available.

PMID:
2252303
24.

Lactamimides: a novel chemical class of calcium antagonists with diltiazem-like properties.

Palfreyman MG, Dudley MW, Cheng HC, Mir AK, Yamada S, Roeske WR, Obata T, Yamamura HI.

Biochem Pharmacol. 1989 Aug 1;38(15):2459-65.

PMID:
2757648
25.

The effects of chronic treatment with amitriptyline and MDL 72394 on the control of 5-HT release in vivo.

Sleight AJ, Smith RJ, Marsden CA, Palfreyman MG.

Neuropharmacology. 1989 May;28(5):477-80.

PMID:
2725855
26.

Effect of acute and chronic MDL 73,147EF, a 5-HT3 receptor antagonist, on A9 and A10 dopamine neurons.

Sorensen SM, Humphreys TM, Palfreyman MG.

Eur J Pharmacol. 1989 Apr 12;163(1):115-8.

PMID:
2744086
27.

MDL 72,974: a potent and selective enzyme-activated irreversible inhibitor of monoamine oxidase type B with potential for use in Parkinson's disease.

Zreika M, Fozard JR, Dudley MW, Bey P, McDonald IA, Palfreyman MG.

J Neural Transm Park Dis Dement Sect. 1989;1(4):243-54.

PMID:
2597310
28.

Chronic MAO A and MAO B inhibition decreases the 5-HT1A receptor-mediated inhibition of forskolin-stimulated adenylate cyclase.

Sleight AJ, Marsden CA, Palfreyman MG, Mir AK, Lovenberg W.

Eur J Pharmacol. 1988 Sep 23;154(3):255-61.

PMID:
3234480
29.
30.

Design and early clinical evaluation of selective inhibitors of monoamine oxidase.

Palfreyman MG, McDonald IA, Bey P, Schechter PJ, Sjoerdsma A.

Prog Neuropsychopharmacol Biol Psychiatry. 1988;12(6):967-87.

PMID:
3266532
31.

Inhibition of rat aorta semicarbazide-sensitive amine oxidase by 2-phenyl-3-haloallylamines and related compounds.

Lyles GA, Marshall CM, McDonald IA, Bey P, Palfreyman MG.

Biochem Pharmacol. 1987 Sep 1;36(17):2847-53.

PMID:
3632710
32.

Enzyme-activated/mechanism-based inhibitors.

Palfreyman MG, Bey P, Sjoerdsma A.

Essays Biochem. 1987;23:28-81. Review. No abstract available.

PMID:
3331367
33.

Monoamine receptor sensitivity changes following chronic administration of MDL 72394, a site-directed inhibitor of monoamine oxidase.

Palfreyman MG, Mir AK, Kubina M, Middlemiss DN, Richards M, Tricklebank MD, Fozard JR.

Eur J Pharmacol. 1986 Oct 14;130(1-2):73-89.

PMID:
3780861
34.

The rational design of suicide substrates of amine oxidases.

Palfreyman MG, McDonald IA, Bey P, Danzin C, Zreika M, Lyles GA, Fozard JR.

Biochem Soc Trans. 1986 Apr;14(2):410-3. No abstract available.

PMID:
3086155
35.

Unsaturated heterocyclic amines as potent time-dependent inhibitors of dopamine beta-hydroxylase.

Bargar TM, Broersma RJ, Creemer LC, McCarthy JR, Hornsperger JM, Palfreyman MG, Wagner J, Jung MJ.

J Med Chem. 1986 Mar;29(3):315-7. No abstract available.

PMID:
3950911
36.

(Z)-2-(2,4-Dichlorophenoxy)methyl-3-fluoroallylamine (MDL 72638): a clorgyline analogue with surprising selectivity for monoamine oxidase type B.

McDonald IA, Palfreyman MG, Zreika M, Bey P.

Biochem Pharmacol. 1986 Jan 15;35(2):349-51. No abstract available.

PMID:
3753647
38.

Inhibition of monoamine oxidase selectively in brain monoamine nerves using the bioprecursor (E)-beta-fluoromethylene-m-tyrosine (MDL 72394), a substrate for aromatic L-amino acid decarboxylase.

Palfreyman MG, McDonald IA, Fozard JR, Mely Y, Sleight AJ, Zreika M, Wagner J, Bey P, Lewis PJ.

J Neurochem. 1985 Dec;45(6):1850-60.

PMID:
3840523
39.

The functional consequences of inhibition of monoamine oxidase type B: comparison of the pharmacological properties of L-deprenyl and MDL 72145.

Fozard JR, Zreika M, Robin M, Palfreyman MG.

Naunyn Schmiedebergs Arch Pharmacol. 1985 Nov;331(2-3):186-93.

PMID:
3937059
40.

Effect of chronic apomorphine on the development of denervation supersensitivity.

Robin M, Forler C, Palfreyman MG.

Pharmacol Biochem Behav. 1985 Apr;22(4):547-51.

PMID:
3921992
41.

Enzyme-activated irreversible inhibitors of monoamine oxidase: phenylallylamine structure-activity relationships.

McDonald IA, Lacoste JM, Bey P, Palfreyman MG, Zreika M.

J Med Chem. 1985 Feb;28(2):186-93.

PMID:
3968682
42.

MDL 72145, an enzyme-activated irreversible inhibitor with selectivity for monoamine oxidase type B.

Zreika M, McDonald IA, Bey P, Palfreyman MG.

J Neurochem. 1984 Aug;43(2):448-54.

PMID:
6736960
43.
45.

(E)-2-(3,4-dimethoxyphenyl)-3-fluoroallylamine: a selective, enzyme-activated inhibitor of type B monoamine oxidase.

Bey P, Fozard J, Lacoste JM, McDonald IA, Zreika M, Palfreyman MG.

J Med Chem. 1984 Jan;27(1):9-10. No abstract available.

PMID:
6690689
47.

Total GABA and homocarnosine in CSF as indices of brain GABA concentrations.

Palfreyman MG, Huot S, Grove J.

Neurosci Lett. 1983 Feb 21;35(2):161-6.

PMID:
6856194
48.

Cerebrospinal fluid GABA as an index of brain GABA activity.

Grove J, Palfreyman MG, Schechter PJ.

Clin Neuropharmacol. 1983;6(3):223-9. No abstract available.

PMID:
6313185
49.

Chronic elevation of brain GABA by gamma-vinyl GABA treatment does not alter the sensitivity of GABAergic or dopaminergic receptors in rat CNS.

Gardner CR, Mallorga P, Klein J, Huot-Olivier S, Palfreyman MG.

Psychopharmacology (Berl). 1983;79(2-3):130-6.

PMID:
6302725
50.

Supplemental Content

Loading ...
Support Center